Stock ATXS ASTRIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
9.08 USD +0.89% Intraday chart for Astria Therapeutics, Inc. -0.22% +18.23%
May. 21 Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $29, Maintains Outperform Rating MT
May. 09 Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Astria Therapeutics : Corporate Presentation
PU
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
BU
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
BU
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
BU
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $29, Maintains Outperform Rating
MT
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
BU
Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
BU
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating
MT
Astria Therapeutics : - 2024 Proxy Statement
PU
Astria Therapeutics : - 2023 Annual Report
PU
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
BU
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee
CI
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating
MT
Transcript : Astria Therapeutics, Inc. - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATXS Stock
  4. News Astria Therapeutics, Inc.